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echocardiography (TEE). After confirming the position by TEE and multi-angle fluoros-
copy, the occluder was released to seal the LAA ostium. Local and systemic histopathol-
ogy was assessed 30 days after device implantation.
Results: By pre-implant angiography and TEE, the mean diameter of LAA ostium was
15.92.5mm and15.82.5mm, respectively. LAA occlusion devices, clinically indicated
for 1420mm human LAA ostial diameter, were successfully implanted in 6 animals
without pericardial effusion or other procedure- or device-related complications. Post-
operative TEE showed all devices in the intended positions achieving successful closure
of all LAA ostia (Figure a). Minimal peri-device leaks ( 3mm jet) were noted in 2/6
cases. Animals experienced no adverse events over 30 days post-implant. Histological
analysis showed adequate deployment and complete circumferential occlusion of all 6
appendages after 30 days. Full endothelial coverage of the luminal aspect of the occluder
was found with no surface thrombosis (Figure b). No adverse histology findings were
noted in the myocardia, mitral valves, kidneys or brains.
Conclusions: In a 30-day canine study the Coherex WaveCrestTM demonstrated safe
deployment, durable LAA occlusion and favorable biocompatibility.
TCT-765
First In-Vivo Evaluation of the Ultrasept Left Atrial Appendage Closure
Device
Yanping Cheng1, Gerard Conditt1, Genghua Yi1, Alyssa Wagner1, Patricia Mount1,
Armando Tellez1, Serge Rousselle2, Greg Kaluza1, Juan Granada1
1Cardiovascular Research Foundation, Orangeburg, NY, 2Alizée Pathology, LLC,
Thurmont, MD
Background: Left atrial appendage (LAA) occlusion aims to reduce the risk of stroke in
atrial fibrillation patients. In this study, we evaluated the feasibility and long-term safety of the
Ultrasept LAA closure device (Figure a)(Cardia Inc., Eagan, MN) in a canine model.
Methods: Trans-septal puncture and device deployment was guided under fluoroscopy and
transesophageal echo (TEE) in 5 dogs. First, the distal cylindrical bulb was released and
secured to the appendage wall with hooks and then the proximal sail was unfolded and covered
the LAA ostium. Rotational angiography, TEE and histology outcomes were assessed 30 days
following implantation.
Results: Pre-operative TEE showed mean diameter of the LAA ostium 17.21.6mm,
depth 18.51.7mm and landing zone for the distal bulb 12.81.3mm. The mean bulb
diameter implant was 16.81.8 mm. Post-operative TEE showed adequate position and
successful occlusion in all implanted devices. Small pericardial effusion related to
multiple device attempts was noted in 1 animal. At 30 days, TEE showed full occlusion
of all LAA ostia (Figure b) besides a minimal peri-device leak (3mm) in 1 animal. No
pericardial effusion or device-related thrombus formation were found. Histological
analysis confirmed circumferential occlusion of all appendages and complete neointimal
coverage on the luminal aspect of the occluder (Figure c).
Conclusions: The percutaneous delivery of the Ultrasept LAA occlusion device was
feasible and safe in a canine model. At 30 days, all devices displayed complete healing
and occlusion of the LAA without any adverse events.
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Background: Following strong evidence that the left atrial appendage (LAA) is the site
of the majority of thrombus formation within the left atrium in patients with non-valvular
atrial fibrillation, non-pharmacological approaches to LAA exclusion have been devel-
oped and shown to be effective. We aim to assess the cumulative experience of a single
operator using a strict set of deployment and release criteria for the Amplatzer Cardiac
Plug (ACP, St. Jude Medical, Plymouth, MN) and the impact of these criteria on
procedural success and complications.
Methods: Procedural and in-hospital outcomes of LAA occlusion performed by a single
operator using the ACP in 100 anticoagulant ineligible patients with a high stroke risk
were assessed.
Results: One hundred patients with a mean CHADS2 score of 3.211.23 underwent
catheterization for closure of LAA with the ACP. The mean landing zone as assessed by
TEE was 20.013.21 mm, and 20.83.19 mm by fluoroscopy. The mean difference
between the TEE and the fluoroscopic measurements was 0.81.13 mm. Device
deployment was successful in 100/100 attempted cases with a mean deployed device size
of 24.363.27 mm. In 82 of the 100 cases the first device selected was implanted.
Procedural and in-hospital complications were limited to a single case of pericardial
tamponade and one post-procedural pulmonary oedema both of which were adequately
treated with no long-term sequelae.
Conclusions: In this single operator report, LAA occlusion using the double element
ACP can be safely performed with excellent success rates. Using very specific deploy-
ment success, stability and release criteria, this device can achieve LAA occlusion with
extremely low complication rates in an extremely frail oral anticoagulant ineligible
population with multiple co-morbidities.
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Background: Little data exist on the long-term outcomes following LAA closure in
patients with absolute contraindication for warfarin.
Methods: A total of 52 patients (mean age: 74 8 years, median CHADS2 score: 3
[2-4]) underwent LAA closure using the ACP device in 7 Canadian centers. Most patients
received short-term (1-3 months) dual antiplatelet therapy following the procedure and
single antiplatelet therapy thereafter, and no patient was lost to follow-up (12 months in
all patients). Transesophageal echocardiography (TEE) was performed in 74% of patients
at 6-month follow-up. Peridevice residual leak was defined as mild (flow width: 1-3 mm)
or severe (flow width: 3 mm).
Results: The procedure was successful in 98.1% of the patients, and was associated with
a low rate of periprocedural complications (device embolization: 1.9%, no stroke or
pericardial effusion). At a mean follow-up of 20  5 months, the rates of death, stroke,
systemic embolism, severe pericardial effusion, and major bleeding were 5.8%, 1.9%, 0%,
1.9%, and 1.9%, respectively. TEE at follow-up showed the presence of mild peridevice
leak in 16.2% of patients. There were no cases of device thrombosis.
Conclusions: In patients with NVAF at high risk for cardioembolism and absolute
contraindication for anticoagulation, LAA closure using the ACP device followed by
dual/single antiplatelet therapy was associated with a very low rate of cardioembolic and
bleeding events at 2-year follow-up. No cases of severe residual leak or device thrombosis
were observed at 6-month follow-up.
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